Covid-19 roundup: Inovio nabs $3 million and a development partner for its vaccine that's still on partial hold; Slaoui proposes halving Moderna vaccine doses as distribution lags

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

With its vaccine candidate finally in Phase II, Inovio is bagging $3 million in a partnership deal with Advaccine Biopharmaceuticals Suzhou to develop and commercialize …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Inovio nabs $3 million and a development partner for its vaccine that's still on partial hold; Slaoui proposes halving Moderna vaccine doses as distribution lags

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Covid-19 roundup: In­ovio nabs $3 mil­lion and a de­vel­op­ment part­ner for its vac­cine that's still on par­tial hold; Slaoui pro­pos­es halv­ing Mod­er­na vac­cine dos­es as dis­tri­b­u­tion lags

Senior Editor

Editor

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Covid-19 roundup: Inovio nabs $3 million and a development partner for its vaccine that's still on partial hold; Slaoui proposes halving Moderna vaccine doses as distribution lags